Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing
This article was originally published in The Pink Sheet Daily
Executive Summary
The traditional pattern of Japanese firms outlicensing their products for the West is shifting as the U.S. market looks increasingly appealing compared to Japan’s price controls and sagging economy. Major Japanese pharmas have been building U.S. development capability, resulting in a full pipeline of products to be developed and marketed directly in the U.S.
You may also be interested in...
The Quality Lowdown: Corporate Culture And Site Complexity Can Pose Challenges
Quality and the measure of a firm: Toyobo’s particulates and resins, Galenicko’s sanitation, Breckenridge’s product chemistry and Fujifilm’s cross-contamination risk.
Optimer Eyes Early 2010 Debut For Diarrhea Meds
Prulifloxacin proves positive in Phase III and early results for soon-to-end OPT-80 study look good, CEO says.
Optimer Eyes Early 2010 Debut For Diarrhea Meds
Prulifloxacin proves positive in Phase III and early results for soon-to-end OPT-80 study look good, CEO says.